All In Biotech

Free tool

FAERS Monitor: Bylvay

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215498 or its brand name (Bylvay, Odevixibat). Reports on generic versions are filed under their own applications.

Reports

398

Serious

162

41% of reports

Hospitalization

75

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus106
  • diarrhoea99
  • off label use79
  • drug ineffective39
  • liver transplant36
  • product dose omission issue27
  • abdominal pain upper25
  • hepatic enzyme increased25
  • abdominal pain22
  • blood bilirubin increased22
  • alanine aminotransferase increased20
  • bile acids increased20
  • vomiting20
  • nausea16
  • aspartate aminotransferase increased15

Reports by year received

View as table
YearReports
20214
202252
202348
202460
2025107
2026127

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,761 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bile acids increasedSignal206738.74276.0113,609
liver transplantSignal36528.5386.418,253
blood bilirubin increasedSignal2243.128.7863
hepatic enzyme increasedSignal2519.413.3419
alanine aminotransferase increasedSignal2017.211.2290
aspartate aminotransferase increasedSignal1514.99.1182
pruritusSignal10614.612.41,352
diarrhoeaSignal998.16.8629
abdominal pain upperSignal256.44.4110
abdominal painSignal225.03.367
product dose omission issueSignal274.93.480
off label useSignal794.83.9242
vomitingSignal202.21.513
drug ineffective391.61.28
nausea161.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.